文献速递神经肿瘤

多端口导管增强对流输送拓扑替康时提高输注速率的初步试验结果

Results of a Pilot Trial of Infusion Rate Escalation During Convection-Enhanced Delivery of Topotecan with a Multiport Catheter.
PubMed 文献 · World Neurosurg · 2025-12-02

该单中心初步试验对3例复发性高级别胶质瘤患者的强化肿瘤行速率递增的拓扑替康对流增强输送,起始速率5 μL/min/微导管,最终达20 μL/min/微导管时出现部分反流。所有病例均覆盖强化与非强化肿瘤,Vd/Vi比0.7–1.3,未发生≥3级治疗相关不良事件。

要点

  • 提高输注速率可克服强化肿瘤的液体外流,增大分布容积。
  • 20 μL/min/微导管时出现部分反流,未再继续递增。
  • 3例患者均耐受良好,无≥3级治疗相关不良事件。

核心结论

  • 提高输注速率可增大强化肿瘤组织的分布容积。

研究设计与样本

  • 单中心、经机构审查委员会批准的初步试验,纳入3例复发性高级别胶质瘤患者。
  • 手术置入单根Cleveland多端口导管至强化肿瘤,行4小时实时MRI可视下输注拓扑替康与钆-DTPA。
  • 实施患者内和患者间速率递增。

主要发现

  • 患者1初始输注速率为5 μL/min/微导管(共4根),患者3最终输注速率为20 μL/min/微导管。
  • 在20 μL/min/微导管速率下观察到部分反流,因此未进一步递增。
  • 所有病例均覆盖强化和非强化肿瘤,Vd/Vi比为0.7至1.3。
  • 患者耐受良好,无常见不良事件术语标准≥3级治疗相关不良事件。

临床怎么用

  • 对于强化肿瘤,可考虑通过速率递增提高对流增强输送的分布容积。
  • 速率递增需在实时MRI监测下进行,注意反流征象。

局限性

  • 样本量仅3例,为初步试验。
  • 单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Volume of distribution (Vd) during convection-enhanced delivery is impacted by the physical characteristics of the tissue being treated. For glioblastoma, Vd is substantially higher in noncontrast-enhancing tumor than in contrast-enhancing tumor due to higher infusate efflux in enhancing tumor. We hypothesized that increasing the infusion rate could overcome the infusate efflux rate in enhancing tumor to improve the Vd to volume of infusion ratio and provide better tumor coverage. METHODS: A single-center, institutional review board-approved pilot study was conducted to perform rate-escalated delivery of Topotecan with gadolinium-DTPA to contrast-enhancing recurrent high-grade glioma. A single Cleveland Multiport Catheter was surgically placed into enhancing tumor and then a 4-hour infusion was performed with real-time magnetic resonance imaging visualization. Intrapatient and interpatient rate escalation was performed. RESULTS: Three patients with recurrent high-grade glioma were enrolled and treated. The initial infusion rate for patient 1 was 5 μL/minute per microcatheter (4 total) and the final infusion rate for the third patient was 20 μL/minute per microcatheter. We observed partial backflow at this rate and therefore did not escalate higher. There was coverage of both enhancing and nonenhancing tumor in all cases, and the Vd/volume of infusion ratio ranged from 0.7 to 1.3. The patients tolerated the treatments well; there were no common terminology criteria for adverse events Grade 3 or higher treatment-related adverse events. The higher efflux rate associated with contrast-enhancing tumor tissue can be overcome with sufficient infusion rate escalation. CONCLUSIONS: Increasing the rate of infusion can allow for larger Vd into enhancing tumor tissue.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Liu JKC, Tran N, Piteo C, et al. Results of a Pilot Trial of Infusion Rate Escalation During Convection-Enhanced Delivery of Topotecan with a Multiport Catheter. World Neurosurg. 2025. PMID: 41344399. doi:10.1016/j.wneu.2025.124696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。